Literature DB >> 3409170

Target organ disposition and plasma pharmacokinetics of doxorubicin incorporated into albumin microspheres after intrarenal arterial administration.

D J Kerr1, N Willmott, J H McKillop, J Cummings, H J Lewi, C S McArdle.   

Abstract

We synthesized doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH)-loaded human albumin microspheres (containing approximately 1% doxorubicin w/w) between 15 and 20 micron in diameter. Intrarenal arterial administration of 99mTC-labeled microspheres demonstrated a high renal entrapment ratio (97% of recovered radioactivity). The pharmacokinetics and metabolism of doxorubicin are different when it is administered in microspherical form. Peak plasma levels are lower (16 ng/ml versus 135 ng/ml) compared with treatment by a doxorubicin solution. Histologic studies showed that the microspheres were trapped within capillaries and small arterioles in the renal vascular arcade. It is apparent that chemoembolization with doxorubicin-loaded microspheres significantly reduces systemic exposure to the antineoplastic agent, and maintains intrarenal drug levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409170     DOI: 10.1002/1097-0142(19880901)62:5<878::aid-cncr2820620505>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Formation and characterization of cisplatin-loaded poly(benzyl l-glutamate) microspheres for chemoembolization.

Authors:  C Li; D J Yang; S Nikiforow; W Tansey; L R Kuang; K C Wright; S Wallace
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

2.  Is liver to lung shunting in colorectal liver metastasis the cause of toxicity following treatment with cytotoxic microsphere aggregates?

Authors:  T W Hennigan; S Earlam; T G Allen-Mersh
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

3.  Regional chemotherapy for inoperable renal carcinoma: a method of targeting therapeutic microspheres to tumour.

Authors:  J H Anderson; N Willmott; R Bessent; W J Angerson; D J Kerr; C S McArdle
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.